ANTICOV Trial
A Policy Advocacy Manager at DNDi develops and implements advocacy strategies, conducts research and analysis, creates policy content, and supports regional and global policy initiatives to advance R&D innovation for neglected populations.
The ANTICOV clinical trial aimed to identify treatments to treat mild and moderate cases of COVID-19 early and prevent hospitalizations in low-resource settings across Africa, Asia, and Latin America. Launched in September 2020 by a 27-organization consortium coordinated by the Drugs for Neglected Diseases initiative (DNDi), it was one of the largest multi-country trials focusing exclusively on mild and moderate COVID-19 cases. The study was completed in December 2022, and its collaborative momentum led to the creation of the PANTHER platform to strengthen pandemic preparedness in Africa.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for ANTICOV Trial.
ANTICOV Trial didn’t post a salary, so this is our estimate from similar listings.
Sr. Advocacy Communications Lead
Fairfax Heart Assoc
Associate Director, UN Advocacy
internationalrescuecommittee.org
Policy & Advocacy Manager, R&I
AstraZeneca
Associate Director (m/f/x), Policy, Advocacy & Government Affairs – Iberia
CSL
Technical Manager, Advocacy, Regulatory, and Policy
International Federation of Accountants
Senior Manager, Advocacy Content Development
ASHP